Literature DB >> 7602346

Contralateral breast cancer: annual incidence and risk parameters.

P Broët1, A de la Rochefordière, S M Scholl, A Fourquet, V Mosseri, J C Durand, P Pouillart, B Asselain.   

Abstract

PURPOSE: To screen for factors that might predict the risk of developing metachronous contralateral breast cancer (CBC), taking into account the influence of local or distant recurrence, and to assess the annual incidence of CBC. PATIENTS AND METHODS: Of 4,748 women with invasive unilateral breast cancer, clinical stage I to IIIa, treated between 1981 and 1987, 282 metachronous CBCs were diagnosed. Due to competing risks between the occurrence of CBC and other events, several options for multivariate analysis were considered.
RESULTS: The median follow-up time was 80 months (range, 1 to 158). The cumulative rate of CBC was 4.1% +/- 0.3% at 5 years, and the annual incidence rate of CBC increased slowly, while the risk of local recurrence and metastases decreased after the fourth year. Whichever model we chose, age less than 55 years (relative risk [RR] = 1.40) at the time of diagnosis of the first breast cancer, as well as the presence of lobular type carcinoma (RR = 1.50), was associated with an increased risk of developing a tumor in the contralateral breast. Adjuvant chemotherapy significantly decreased (RR = 0.54) the risk of CBC.
CONCLUSION: Lobular histology and age less than 55 years are found to increase the risk of CBC, while adjuvant chemotherapy significantly decreased the risk of CBC. The progressive rise in the annual incidence rates of CBC, together with the absence of a link between clinical prognostic factors of the first cancer and CBC, suggested that CBC can be considered as a second primary breast cancer.

Entities:  

Mesh:

Year:  1995        PMID: 7602346     DOI: 10.1200/JCO.1995.13.7.1578

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  32 in total

Review 1.  Chemoprevention of breast cancer with fenretinide.

Authors:  R Torrisi; A Decensi; F Formelli; T Camerini; G De Palo
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk.

Authors:  Robert T Chatterton; Richard E Heinz; Angela J Fought; David Ivancic; Claire Shappell; Subhashini Allu; Susan Gapstur; Denise M Scholtens; Peter H Gann; Seema A Khan
Journal:  Horm Cancer       Date:  2016-02-22       Impact factor: 3.869

3.  Preoperative Breast Magnetic Resonance Imaging and Contralateral Breast Cancer Occurrence Among Older Women With Breast Cancer.

Authors:  Shi-Yi Wang; Jessica B Long; Brigid K Killelea; Suzanne B Evans; Kenneth B Roberts; Andrea Silber; Cary P Gross
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

Review 4.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

5.  A case report of male breast cancer in a very young patient: what is changing?

Authors:  Marcelo Madeira; André Mattar; Rodrigo José Barata Passos; Caroline Dornelles Mora; Luiz Henrique Beralde Vilar Mamede; Viviane Hatsumi Kishino; Thomas Zurga Markus Torres; Andressa Fernandes Rodrigues de Sá; Roberto Euzébio dos Santos; Luiz Henrique Gebrim
Journal:  World J Surg Oncol       Date:  2011-02-03       Impact factor: 2.754

6.  The diffuse type of invasive lobular carcinoma of the breast: morphology and prognosis.

Authors:  Tibor Tot
Journal:  Virchows Arch       Date:  2003-08-22       Impact factor: 4.064

7.  Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study.

Authors:  Andrea Veronesi; Gianmaria Miolo; Maria D Magri; Diana Crivellari; Simona Scalone; Ettore Bidoli; Davide Lombardi
Journal:  BMC Cancer       Date:  2010-05-14       Impact factor: 4.430

8.  Loss of heterozygosity or allele imbalance in histologically normal breast epithelium is distinct from loss of heterozygosity or allele imbalance in co-existing carcinomas.

Authors:  Pamela S Larson; Antonio de las Morenas; Sheila R Bennett; L Adrienne Cupples; Carol L Rosenberg
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

Review 9.  HER2-positive male breast cancer: an update.

Authors:  Laura Ottini; Carlo Capalbo; Piera Rizzolo; Valentina Silvestri; Giuseppe Bronte; Sergio Rizzo; Antonio Russo
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-10-04

10.  Surveillance mammography among female Department of Defense beneficiaries: a study by race and ethnicity.

Authors:  Lindsey Enewold; Katherine A McGlynn; Shelia H Zahm; Ismail Jatoi; William F Anderson; Abegail A Gill; Craig D Shriver; Kangmin Zhu
Journal:  Cancer       Date:  2013-08-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.